MESO Inc.

Troy, NY, United States

MESO Inc.

Troy, NY, United States
SEARCH FILTERS
Time filter
Source Type

NEW YORK and MELBOURNE, Australia, April 06, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has received A$3.7 million from the Australian Government for Research & Development (R&D) activities conducted during the 2016 financial year. The funds were provided to Mesoblast under the Government's R&D Tax Incentive Program, which is designed to support industry innovation. About Mesoblast Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties   and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


NEW YORK and MELBOURNE, Australia, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that the Phase 2a trial of its Mesenchymal Precursor Cells (MPCs) for prevention of radiographic and clinical features of knee osteoarthritis after traumatic injury has been published in the peer-reviewed journal Arthritis Research & Therapy. The results showed that a single intra-articular injection of Mesoblast’s product candidate MPC-75-IA reduced cartilage loss and bone changes by six months, and improved pain and function for over two years, when compared to controls. The paper, entitled ‘Safety, tolerability, clinical and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients post anterior cruciate ligament reconstruction: a controlled double-blind randomized trial’, concluded that MPCs may modulate the inflammation-related pathological processes that are associated with post-traumatic knee osteoarthritis. The trial's senior author, Professor Flavia Cicuttini, Head Musculoskeletal Unit, Department of Epidemiology and Preventive Medicine School of Public Health and Preventive Medicine at Monash University, Australia, said: “As there are no treatments that slow progression of osteoarthritis, these results are very exciting for a population who are at high risk of developing this crippling condition.” “In this study we found that a single injection of 75 million mesenchymal precursor cells was well tolerated and appeared to slow the onset of a number of the early changes at the knee that are common following knee injury and signify the development of knee osteoarthritis. Larger studies are warranted to confirm whether this treatment will slow or even prevent the development of knee osteoarthritis following early joint injuries,” stated Professor Cicuttini. About Post-Traumatic Osteoarthritis Osteoarthritis (OA) is a common and debilitating disease that affects approximately 27 million people in the United States4.  Post-traumatic OA of the knee, hip and ankle accounts for approximately 5.6 million cases of OA in the United States4. There are approximately 250,000 cases of ACL tears annually in the USA, more than 70% of ACL reconstructions occur in patients under the age of 65 years4,5. Despite corrective ACL surgery, as many as 80% of knees post-ACL injury will progress to radiographic and symptomatic OA after 5 to 15 years6. Similar outcomes are seen with the approximately 1 million meniscal reconstruction procedures performed annually in the United States7. While existing treatments for post-traumatic OA predominantly focus on reducing pain and inflammation, none have been shown to restore joint structural changes or delay the onset and/or progression of OA. ACL reconstruction is considered to be a cost-effective treatment strategy, however in the United States there is still a significant annual cost of about $2.8 billion attributable to the long-term development of OA8. An innovative therapy that demonstrates disease modifying effects on OA development or progression would be expected to deliver significant annual societal cost savings. 1 https://www.cdc.gov/injury/erpo/icrc/2009/1-r49-ce001495-01.html 2 Arthritis & Rheumatology; Early Knee Osteoarthritis Is Evident One Year Following Anterior Cruciate Ligament Reconstruction: A Magnetic Resonance Imaging Evaluation; Adam G. Gulvenor, et al; April 2015 3 American Journal of Sports Medicine; The long-term consequence of anterior cruciate ligament and meniscus injuries;35:1756–69, Lohmander LS, Englund PM, Dahl LL, Roos EM.; 2007 4 Thomas A, Hubbard-Turner T, Wikstrom E (2017) Epidemiology of Psttraumatic Osteoarthritis. Journal of Athletic Training 52(6): 491-496 5 Abrams G, Frank R, Gupta A (2013) Trends in Meniscus Repair and Meniscectomy in the United States, 2005-2011. The American Journal of Sports Medicine: 1-7 6 Simon D, Mascarenhas R, Saltzman B (2015) The Relationship between Anterior Cruciate Ligament Injury and Osteoarthritis of the Knee. Advances in Orthopedics: 1-12 7 Verdonk R, Verdonk P, Huysse W (2011) Tissue in­ Growth After Implantation of a Novel, Biodegradable Polyurethane Scaf­fold for Treatment of Partial Meniscal Lesions. The American Journal of Sports Medicine: 39:774-782 8 Mather R, Koenig L, Kocher M (2013) Societal and Economic Impact of Anterior Cruciate Ligament Tears. The Journal of Bone and Joint Surgery: 95:1751-9 About Mesoblast Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. For more information, please visit www.mesoblast.com. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward- looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


Melbourne, Australia and New York, May 24, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today provided the market with operational highlights and financial results for the three and nine month reporting periods ended March 31, 2017.  During the reporting period, the Company achieved a major milestone in its valuable heart failure Phase 3 program, maintained momentum in its additional Phase 3 trials, and continued to reduce spend.        During the first nine months of FY2017, the Company executed its planned operational streamlining and re-prioritization of projects to successfully absorb the incremental costs of the MPC-150-IM Phase 3 program in advanced chronic heart failure (CHF). Due to these measures, cash outflows for R&D product support costs, manufacturing, and management & administration were reduced for the nine months of FY2017 by US$16.4 million (24%), compared with the nine months of FY2016. For the third quarter of FY2017, cash outflows for the same operational activities were reduced by US$5.1 million (23%) compared with the third quarter of FY2016. These savings enabled the Company to allocate sufficient funds for the CHF Phase 3 trial through to the successful interim futility analysis of the trial’s efficacy endpoint in early April 2017. After absorbing the incremental R&D costs associated with the CHF Phase 3 trial, together with increased spend on advancing the other Tier 1 product candidates in Phase 3 trials, total operating cash outflows were reduced by US$0.8 million as compared to the first nine months of FY2016. As of March 31, 2017, the Company had cash reserves of US$69.1 million following a capital raising of approximately US$40 million. As previously announced, Mesoblast has established an equity facility for up to A$120 million/US$90 million, to be used at its discretion over the next two years to provide additional funds as required. The Company intends to partner one or more of its four Tier 1 product candidates in order to increase cash reserves and further reduce cash burn. As previously announced, the Company is in exclusive negotiations with Mallinckrodt Pharmaceuticals in regard to a potential commercial and development partnership for two of its lead product candidates. Key operational highlights for the quarter with respect to the Company’s four Tier 1 product candidates were: MPC-150-IM is being developed for advanced and end-stage chronic heart failure (CHF) in New York Heart Association (NYHA) Class II/III and Class IV patients: MPC-300-IV is being developed for biologic refractory rheumatoid arthritis (RA): MPC-06-ID is being developed for chronic low back pain (CLBP) due to disc degeneration: MSC-100-IV is being developed for Acute Graft Versus Host Disease (aGVHD): Financial Results for the Three Months Ended March 31, 2017 (third quarter) (in U.S. Dollars) The Company continued to execute its planned operational streamlining and re-prioritization of projects to successfully absorb the incremental costs of the MPC-150-IM Phase 3 program in CHF. Due to these measures, cash outflows for R&D product support costs, manufacturing, and management & administration were reduced by $5.1 million (23%) for the third quarter of FY2017, compared with the third quarter of FY2016. These reductions comprised: $3.9 million within manufacturing and $1.2 million within R&D product support costs. There was an improvement of $8.2 million (39%) in the loss before income tax for the third quarter of FY2017, compared with the third quarter of FY2016. This was primarily due to non-cash items that do not affect our cash reserves, such as remeasurement of contingent consideration, finance costs and foreign exchange movements within other operating income and expenses. Additional items which impacted the loss before income tax movement were: Our net loss attributable to ordinary shareholders was $9.8 million, or 2.46 cents per share, for the third quarter of FY2017, compared with $16.9 million, or 4.49 cents per share, for the third quarter of FY2016. Financial Results for the Nine Months Ended March 31, 2017 (the nine months) (in U.S. Dollars) The Company continued to execute its planned operational streamlining and re-prioritization of projects to successfully absorb the incremental costs of the MPC-150-IM Phase 3 program in CHF. Due to these measures, cash outflows for R&D product support costs, manufacturing, and management & administration were reduced by $16.4 million (24%), compared with the nine months of FY2016. These reductions comprised: $11.1 million in manufacturing, $4.5 million within R&D product support costs and $0.8 million within management & administration. There was an increase of $2.3 million (4%) in the loss before income tax for the nine months of FY2017, compared with the nine months of FY2016. This was primarily due to non-cash items that do not affect our cash reserves, such as remeasurement of contingent consideration, finance costs and foreign exchange movements within other operating income and expenses. Additional items which impacted the loss before income tax movement were: Our net loss attributable to ordinary shareholders was $49.6 million, or 12.87 cents per share, for the nine months of FY2017, compared with $52.4 million, or 14.76 cents per share, for the nine months of FY2016. Mesoblast will be hosting a conference call beginning at 8am AEST on May 25, 2017 / 6pm EST on May 24, 2017.  The conference identification code is 528910. The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/592263cc45e9d25707f89993 To access the call, please dial: This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


GAITHERSBURG, Md.--(BUSINESS WIRE)--Smithers Avanza, a contract research organization (CRO) supporting the pharmaceutical industry, announced that it has added three additional instruments to its bioanalytical laboratory, following up on its recent building expansion; the Hamilton Microlab STAR pipetting workstation, the Meso Scale Discovery (MSD) MESO Sector S 600 plate reader and the Perkin Elmer EnSpire® multimode plate reader. These instruments, along with the recent additions to the physical lab space, increase Smithers Avanza’s capacity for bioanalytical testing. “Growing in line with the needs of our clients is important as we seek to be the best and most reliable partner for independent, CLIA-certified and GLP-compliant testing related to the development of biologics,” said Ira DuBey, Executive Vice President, Bioanalytical Services Division, Smithers Avanza. “These new instruments will help our team to increase volume and efficiency of testing while also playing a role in ensuring timely delivery of study data.” Smithers Avanza has broad and extensive experience in the development and validation of assays used for biotherapeutics development, including assays for pre-clinical applications and all phases of clinical development, Phase I through Phase IV. The CLIA-certified and GLP-compliant laboratory expanded recently, doubling in size to accommodate the increasing demand for bioanalytical services. For more information about the Smithers Avanza portfolio of services and instrumentation, visit http://smithersavanza.com. Smithers Avanza is a contract research organization (CRO) supporting the pharmaceutical industry. Our scientists have expertise in large molecule bioanalysis, assay development, validation, and specimen analysis at our GLP- and GCP-compliant and CLIA-certified laboratory. Smithers Avanza Bioanalytical Services Division supports the development of biologics and vaccines from discovery through phase IV, with expertise that includes bioassays and high sensitivity assays. The services focus primarily on development, validation, and specimen analysis for PK/TK, ADA, bioassays, and biomarker assays. Smithers Avanza also offers preclinical toxicology and vaccine testing at our AAALAC accredited facilities.


NEW YORK and MELBOURNE, Australia, June 22, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) announced that results from the randomized, placebo-controlled 48-patient Phase 2 trial of its proprietary allogeneic Mesenchymal Precursor Cells (MPCs) in patients with biologic refractory rheumatoid arthritis (RA) were presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology held in Madrid June 14-17. The abstract was selected by peer review and presented by the trial’s independent investigators. The EULAR Congress is the key European platform for showcasing innovation in rheumatology and highlighting the latest advances in the field. The 2017 Congress was attended by approximately 14,000 delegates from more than 120 countries. Trial investigator, Dr Suzanne Kafaja, Assistant Clinical Professor in the Division of Rheumatology, Department of Medicine, at the University of California at Los Angeles (UCLA), presented both safety and efficacy outcomes of the trial using pre-specified analyses over the 12-week primary evaluation period, as well as follow-up results over 39 weeks. Dr Kafaja said the trial had met its primary endpoints and the data indicated an early trend to improvements in patient-related outcome measures. “Taken together, these results show promise and support further development of Mesoblast's mesenchymal precursor cells for biologic-refractory rheumatoid arthritis patients, a population with substantial remaining medical need," she said. Major advances in the treatment of RA using biologic agents have resulted in a $19 billion global market in 2016, the majority of which is due to use of anti-TNF agents. The RA population resistant to anti-TNF agents, which constitutes about one-third of patients treated with anti-TNF agents, is the fastest growing branded market segment within the global RA biologics market, and is set to grow further as multiple anti-TNF biosimilars become available. There are approximately 6 million prevalent cases in the United States, Japan, and EU5, with 2.9 million in the United States alone in 20161,2 About Mesoblast Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.  Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


Perez R.,University at Albany | Lorenz E.,University of Oldenburg | Pelland S.,Natural Resources Canada | Beauharnois M.,University at Albany | And 13 more authors.
Solar Energy | Year: 2013

This article combines and discusses three independent validations of global horizontal irradiance (GHI) multi-day forecast models that were conducted in the US, Canada and Europe. All forecast models are based directly or indirectly on numerical weather prediction (NWP). Two models are common to the three validation efforts - the ECMWF global model and the GFS-driven WRF mesoscale model - and allow general observations: (1) the GFS-based WRF- model forecasts do not perform as well as global forecast-based approaches such as ECMWF and (2) the simple averaging of models' output tends to perform better than individual models. © 2013 Elsevier Ltd.


Patent
Meso Inc. and Mano Nanotechnologies Inc. | Date: 2013-08-08

Disclosed herein is a drifting airborne probe that includes a body having an aerodynamic shape that is biologically inspired by a wind dispersible natural seed. The probe includes a total mass of less than 10 grams, a power source operably connected to the body; at least one sensor operably connected to the body for collecting data from the environment and about the environment, a transmitter for transmitting the data operably connected to the body and no active propulsion system. Disclosed herein is also a method for collecting and transmitting data about an environment that includes providing a plurality of these drifting airborne probes. Moreover, a system that utilizes a plurality of these drifting airborne probes is also provided.


Montornes A.,University of Barcelona | Montornes A.,Aws Truepower | Codina B.,University of Barcelona | Zack J.W.,MESO Inc.
Atmospheric Chemistry and Physics | Year: 2015

Although ozone is an atmospheric gas with high spatial and temporal variability, mesoscale numerical weather prediction (NWP) models simplify the specification of ozone concentrations used in their shortwave schemes by using a few ozone profiles. In this paper, a two-part study is presented: (i) an evaluation of the quality of the ozone profiles provided for use with the shortwave schemes in the Advanced Research version of the Weather Research and Forecasting (WRF-ARW) model and (ii) an assessment of the impact of deficiencies in those profiles on the performance of model simulations of direct solar radiation. The first part compares simplified data sets used to specify the total ozone column in six schemes (i.e., Goddard, New Goddard, RRTMG, CAM, GFDL and Fu-Liou-Gu) with the Multi-Sensor Reanalysis data set during the period 1979-2008 examining the latitudinal, longitudinal and seasonal limitations in the ozone profile specifications of each parameterization. The results indicate that the maximum deviations are over the poles and show prominent longitudinal patterns in the departures due to the lack of representation of the patterns associated with the Brewer-Dobson circulation and the quasi-stationary features forced by the land-sea distribution, respectively. In the second part, the bias in the simulated direct solar radiation due to these deviations from the simplified spatial and temporal representation of the ozone distribution is analyzed for the New Goddard and CAM schemes using the Beer-Lambert-Bouguer law and for the GFDL using empirical equations. For radiative applications those simplifications introduce spatial and temporal biases with near-zero departures over the tropics throughout the year and increasing poleward with a maximum in the high middle latitudes during the winter of each hemisphere. © Author(s) 2015.


Montornes A.,University of Barcelona | Codina B.,University of Barcelona | Zack J.W.,MESO Inc. | Sola Y.,University of Barcelona
Atmospheric Chemistry and Physics | Year: 2016

Solar eclipses are predictable astronomical events that abruptly reduce the incoming solar radiation into the Earth's atmosphere, which frequently results in non-negligible changes in meteorological fields. The meteorological impacts of these events have been analyzed in many studies since the late 1960s. The recent growth in the solar energy industry has greatly increased the interest in providing more detail in the modeling of solar radiation variations in numerical weather prediction (NWP) models for the use in solar resource assessment and forecasting applications. The significant impact of the recent partial and total solar eclipses that occurred in the USA (23 October 2014) and Europe (20 March 2015) on solar power generation have provided additional motivation and interest for including these astronomical events in the current solar parameterizations. Although some studies added solar eclipse episodes within NWP codes in the 1990s and 2000s, they used eclipse parameterizations designed for a particular case study. In contrast to these earlier implementations, this paper documents a new package for the Weather Research and Forecasting-Advanced Research WRF (WRF-ARW) model that can simulate any partial, total or hybrid solar eclipse for the period 1950 to 2050 and is also extensible to a longer period. The algorithm analytically computes the trajectory of the Moon's shadow and the degree of obscuration of the solar disk at each grid point of the domain based on Bessel's method and the Five Millennium Catalog of Solar Eclipses provided by NASA, with a negligible computational time. Then, the incoming radiation is modified accordingly at each grid point of the domain. This contribution is divided in three parts. First, the implementation of Bessel's method is validated for solar eclipses in the period 1950-2050, by comparing the shadow trajectory with values provided by NASA. Latitude and longitude are determined with a bias lower than 5 × 10-3 degrees (i.e., ∼ 550 m at the Equator) and are slightly overestimated and underestimated, respectively. The second part includes a validation of the simulated global horizontal irradiance (GHI) for four total solar eclipses with measurements from the Baseline Surface Radiation Network (BSRN). The results show an improvement in mean absolute error (MAE) from 77 to 90 % under cloudless skies. Lower agreement between modeled and measured GHI is observed under cloudy conditions because the effect of clouds is not included in the simulations for a better analysis of the eclipse outcomes. Finally, an introductory discussion of eclipse-induced perturbations in the surface meteorological fields (e.g., temperature, wind speed) is provided by comparing the WRF-eclipse outcomes with control simulations. © 2016 Author(s).


Patent
Meso Ltd | Date: 2010-06-25

Vivarium (100) comprising a housing capable of providing a habitat for an animal wherein the housing comprises plastics material with anti-bacterial properties.

Loading MESO Inc. collaborators
Loading MESO Inc. collaborators